What is HC Wainwright’s Estimate for RYTM FY2025 Earnings?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Research analysts at HC Wainwright raised their FY2025 earnings per share estimates for Rhythm Pharmaceuticals in a research report issued on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($3.10) per share for the year, up from their previous estimate of ($3.13). HC Wainwright currently has a “Buy” rating and a $125.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q4 2025 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.29) EPS and FY2026 earnings at ($1.98) EPS.

Several other equities research analysts also recently weighed in on the stock. Oppenheimer downgraded shares of Rhythm Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Wednesday, November 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday, October 8th. Morgan Stanley restated an “overweight” rating and set a $150.00 price objective on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. Wells Fargo & Company increased their price target on Rhythm Pharmaceuticals from $129.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Zacks Research lowered Rhythm Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Rhythm Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $131.29.

Rhythm Pharmaceuticals Trading Up 2.3%

RYTM stock opened at $108.36 on Thursday. Rhythm Pharmaceuticals has a 1-year low of $45.90 and a 1-year high of $122.20. The stock has a 50-day moving average price of $106.42 and a 200-day moving average price of $100.84. The firm has a market cap of $7.23 billion, a PE ratio of -34.95 and a beta of 2.00.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.10). Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%.The company had revenue of $51.30 million for the quarter, compared to the consensus estimate of $50.71 million.

Insider Activity at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 9,748 shares of the firm’s stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $115.24, for a total value of $1,123,359.52. Following the sale, the insider owned 8,509 shares of the company’s stock, valued at $980,577.16. This trade represents a 53.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Pamela J. Cramer sold 3,350 shares of the business’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $111.00, for a total transaction of $371,850.00. Following the transaction, the insider owned 20,814 shares in the company, valued at $2,310,354. This represents a 13.86% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 15,913 shares of company stock valued at $1,818,963 in the last quarter. Corporate insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC boosted its stake in shares of Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after buying an additional 141 shares during the last quarter. Farther Finance Advisors LLC boosted its position in Rhythm Pharmaceuticals by 1,110.3% in the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after purchasing an additional 322 shares during the last quarter. GAMMA Investing LLC boosted its position in Rhythm Pharmaceuticals by 48.6% in the fourth quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock worth $39,000 after purchasing an additional 118 shares during the last quarter. Optiver Holding B.V. grew its stake in shares of Rhythm Pharmaceuticals by 65.2% during the 3rd quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock valued at $37,000 after purchasing an additional 144 shares during the period. Finally, Osaic Holdings Inc. increased its position in shares of Rhythm Pharmaceuticals by 65.9% during the 2nd quarter. Osaic Holdings Inc. now owns 979 shares of the company’s stock valued at $62,000 after purchasing an additional 389 shares during the last quarter.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.